You are here:

tiotropium, 2.5 microgram, solution for inhalation (Spiriva® Respimat®)

Advice

following a full submission

tiotropium (Spiriva® Respimat®) is accepted for use within NHS Scotland.

Indication under review: As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.

Two phase III RCTs demonstrated that the addition of tiotropium significantly improved lung function and increased the time to the first severe exacerbation compared with placebo in patients with uncontrolled asthma despite treatment with high dose inhaled corticosteroid and a long acting beta2 agonist.

Drug Details

Drug Name: tiotropium, 2.5 microgram, solution for inhalation (Spiriva® Respimat®)
SMC Drug ID: 1028/15
Manufacturer: Boehringer Ingelheim Ltd
Indication: As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 August 2015

Back